



IPP stimulated $V\gamma 2$ cells from HIV+ donors acquire granzyme B expression. PBMC from HIV+ or control donors were expanded with IPP and IL2 for 14 days, cells were stained for flow cytometry before and after expansion with antibodies against $V\gamma 2$, GrB, CD27, and CD45RA. Shown are representative plots of Granzyme B (+ isotype control) in $V\gamma 2^+$ cells on day 14 of the culture. While there are significant differences in post-expansion frequency of $V\gamma 2^+$ cells between HIV+ and control donors, no differences in GrB expression in $V\gamma 2^+$ cells was observed (summarized in Table 2).

Supplemental Table 1

Group	Sample ID	Frequency of GrB+ Cells Among Vg2-					Frequency of GrB+ Cells Among Vg2+					
		Total Vg2-	CD27+/RA+	CD27+ /RA-	CD27- /RA-	CD27- /RA+	Total Vg2+	CD27 +/RA+	CD27+ /RA-	CD27- /RA-	CD27- /RA+	
Control	ND001	28.9	10.7	12.6	25.1	55.3	72.8	82.7	48.8	75.8	86.1	
	ND003	28.2	9.7	13.9	28.2	67.3	73.6	76.3	68.8	77.4	91.7	
	ND004	46.8	7.5	6.4	67.8	71	53.4	45.4	36.7	66.1	80.6	
	ND005	12.7	8.2	4.4	12	31.4	64.3	81.3	44.2	68.1	95.7	
	ND006	46.4	53.6	47.9	31.7	29.2	45.3	50.9	41.3	50.4	38.9	
	ND008	12.3	3.4	6.2	33	30.9	81.8	83.5	70.3	81.3	88	
	ND012	44.5	7.4	11	54.4	68.6	35.9	41.5	32	41.3	52.3	
	ND013	30.7	9.9	9.7	34.6	72.7	75.2	70.1	58	74.4	89.7	
	ND014	36.8	4.5	2.7	12.4	75.1	68.1	30	4.8	2.4	86.7	
	ND015	11.8	4.1	9.3	26	27.2	77.5	78.5	75.6	81.6	90	
	ND016	27.7	4.3	6.6	65.6	60.5	59.7	66.7	51.8	77.6	75	
	ND017	23.2	18.4	6.9	22.4	57.2	47.8	67.1	24.6	47.7	74	
	ND018	20.8	4.3	4.4	53.8	51	45.9	42.9	33	64.3	92.3	
	ND019	24.3	3.6	2.2	25.7	66.1	86.9	92.7	50.3	87.5	97.7	
	ND020	9.1	2.5	3.3	9.6	53.5	34.1	57.8	26.2	29.2	100	
	Averages	26.95	10.14	9.83	33.49	54.47	61.49	64.49	44.43	61.67	82.58	
	StDev	12.60	12.70	11.12	18.67	17.03	16.89	18.76	19.23	23.43	16.92	
	HIV+	PD001	45	35.9	29.6	57.1	74.7	36	60	28.6	54.2	100
		PD002	24.8	12.3	8.6	41.5	53.1	37.9	38.6	9.8	80.8	65
		PD003	22	7.5	5.8	54.7	30.9	28	26.9	33.3	*	25
PD004		21.6	7	9	49.8	48.7	43	22.9	53.8	*	75	
PD005		13.8	3.9	7.9	29.3	35.2	42.5	22.2	47.5	55.6	36.4	
PD006		25.2	8	10.8	64.5	39.9	51	44.1	37	50	85.3	
PD007		29.6	7.9	14.5	37.4	48.5	77.1	53.8	13.9	33.3	93.1	
PD008		32.5	13.1	10.1	49.2	50.2	44.1	44.4	28.9	*	78.9	
PD009		7.9	1.8	3.7	60.6	18.5	31.3	6.3	13	100	73.1	
PD010		25.1	9.4	18.9	68.3	40.1	71.8	37.1	36.2	60	90.6	
PD011		9.3	6.2	5.2	11.3	15.1	24.4	13.2	2.2	*	69.4	
PD012		21.7	4.1	11.1	40.7	58	44.3	*	7.7	50	84.9	
PD014		37.3	10.9	4.5	45.7	79.3	39.8	26	13.9	22.2	60	
PD015		53.6	45.6	12.7	32	84.9	36.8	14.2	25	10.5	46.1	
PD017		25.4	12.4	5.8	29.3	49.1	33	38	34.4	14.3	29.4	
PD018		49	44.3	33.9	37.9	76.5	54.7	63.2	18.4	38.7	77.2	
PD019		8.1	2.5	0.9	5.2	19.9	2.1	1.6	6.9	*	1.2	
PD020		39.2	13.5	13	39.4	77.1	30.3	38.9	25	50	20	
PD021		50.1	28.9	18.9	27.5	87.6	66.2	45.2	30	6.7	78.6	
PD022		39.3	14.6	4.9	14.3	75.5	30.5	40.3	13.2	14.4	44.3	
PD023		24.4	7.4	1.4	19.9	47.2	62.3	24.6	6.1	*	94.4	
Averages		28.80	14.15	11.01	38.84	52.86	42.24	33.08	23.09	42.71	63.23	
StDev		13.67	13.05	8.51	17.44	22.36	17.34	16.95	14.22	26.67	27.91	
T Tests: HIV+ to Controls	0.6806	0.3643	0.7212	0.3841	0.8163	0.0022	0.0000	0.0005	0.0479	0.0228		

* - Insufficient Data for Analysis

Supplemental Table 2

Group	Sample ID	V γ 2 Frequency		GrB+ V γ 2 Cells	
		Day 00	Day 14	Day 00	Day 14
Control	ND001	2.4	87.2	89.8	98.2
	ND006	1.8	47.7	68.4	89.7
	ND007	1.7	58.2	78.4	98.3
	ND015	5.4	60.7	77.5	62.6
	ND018	1.1	31.6	45.9	43.1
	ND019	10.2	89.5	86.9	46.1
	ND020	1.0	25.5	34.8	97.5
	Average	3.37	57.20	68.81	76.50
	StDev	3.36	24.86	20.88	25.15
HIV+	PD001	2.3	23.5	34.4	96.1
	PD003	0.4	1.9	28.0	93.8
	PD006	0.1	5.9	51.0	97.9
	PD007	0.1	6.6	77.1	70.7
	PD009	0.1	0.4	31.3	36.4
	PD010	1.0	64.5	71.8	61.7
	Average	0.67	17.15	48.93	76.10
	StDev	0.87	24.62	21.36	24.50

* p < 0.05